Data Insights

Emavusertib hydrochloride by Curis for Metastatic Melanoma: Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Metastatic Melanoma

Data Insights

Emavusertib hydrochloride by Curis for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Chronic Myelomonocytic Leukemia (CMML)

Data Insights

Emavusertib hydrochloride by Curis for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Data Insights

Emavusertib hydrochloride by Curis for Primary CNS Lymphoma: Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Primary CNS Lymphoma. According to GlobalData,...

Data Insights

Emavusertib hydrochloride by Curis for Myelodysplastic Syndrome: Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...

Data Insights

Emavusertib hydrochloride by Curis for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...

Data Insights

Emavusertib hydrochloride by Curis for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...